Precision Medicine Got Kidney Disease Wrong—Until Now
Explore how variant functionalization is driving the future of mechanism-driven medicines as host Brandon interviews Jason Coloma, CEO of Maze Therapeutics, on Power to the Patients. Jason explains why most gene-disease associations fail to become therapies, how APOL1-mediated kidney disease reveals the power of precision nephrology, and what it actually takes to build an integrated genetics-to-drug-discovery platform.
Episode 25 of the Power to the Patients podcast, hosted by Brandon Li, titled "Precision Medicine Got Kidney Disease Wrong—Until Now" was published on April 1, 2026 and runs 42 minutes.
April 1, 2026 ·42m · Power to the Patients
Summary
Explore how variant functionalization is driving the future of mechanism-driven medicines as host Brandon interviews Jason Coloma, CEO of Maze Therapeutics, on Power to the Patients. Jason explains why most gene-disease associations fail to become therapies, how APOL1-mediated kidney disease reveals the power of precision nephrology, and what it actually takes to build an integrated genetics-to-drug-discovery platform.
Episode Description
Similar Episodes
Apr 9, 2026 ·12m
Apr 5, 2026 ·5m
Apr 3, 2026 ·8m
Mar 30, 2026 ·9m
Mar 28, 2026 ·8m